Larimar Therapeutics, Inc. (LRMR)
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Larimar Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 103.88M shares outstanding
USHeadquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm.
Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform.
The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Leadership
Carole S. Ben-Maimon, M.D.
President and Chief Executive Officer of Larimar Therapeutics, Inc.
Carole S. Ben-Maimon
Chief Executive Officer, President & Director
Michael Celano
Secretary & Chief Financial Officer
Gopi Shankar
Chief Development Officer
Employees
65
Country
US
Sector
Healthcare
Website
larimartx.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Harlow John B. Jr. | President and COO | Grant/Award | 50.0K | -- | Sep 29, 2026 |
| Harlow John B. Jr. | President and COO | Grant/Award | 800.0K | -- | Sep 29, 2026 |
 Hamilton Thomas Edward | Director | Purchase | 50.0K | $166.9K | Jul 6, 2026 |
 LEFF JONATHAN S | Director | Grant/Award | 55.1K | -- | May 19, 2026 |
 Flynn James E | Director | Grant/Award | 55.1K | -- | May 19, 2026 |
| Hamilton Thomas Edward | Director | Grant/Award | 55.1K | -- | May 19, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. | 35.6M | 34.3% | 13F |
Blue Owl Capital Holdings LP · also on 13F· may incl. warrants· filed May 2026 | 10.7M | 10.3% | 13G |
Blue Owl Capital Holdings LP | 9.2M | 8.8% | 13F |
BlackRock, Inc. | 5.7M | 5.5% | 13F |
THE GOLDMAN SACHS GROUP, INC. · also on 13F· may incl. warrants· filed Nov 2024 | 4.5M | 4.3% | 13G |
Defilade Capital Management, L.P. | 3.7M | 3.5% | 13F |
Millennium Management LLC · also on 13F· joint filing· may incl. warrants· filed Apr 2026 | 3.6M | 3.5% | 13G |
DRIEHAUS CAPITAL MANAGEMENT LLC | 3.2M | 3.0% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Apr 2025 | 3.1M | 3.0% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | 2.9% | 13F |
Insiders
- Harlow John B. Jr.President and COO
- Hamilton Thomas EdwardDirector
- LEFF JONATHAN SDirector
- Flynn James EDirector
- THOMAS FRANK EDirector
- Truitt JosephDirector
- SHERMAN JEFFREY WDirector
- Shankar GopiChief Development Officer
- BEN-MAIMON CAROLEPresident and CEO
- Celano MichaelChief Financial Officer
based on 103.88M shares outstanding
US30d Avg
1.58M
60d Avg
1.43M
90d Avg
1.33M